At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 16 enrolled
Drug / intervention
Bevacizumab +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Steroid vs. Anti-vascular Endothelial Growth Factor for Diabetic Macular Edema Prior to Phacoemulsification
In Brief
A Phase 4 clinical trial evaluating Bevacizumab, Ranibizumab, and 2 other interventions for Diabetic Macular Edema and Cataract. Completed, enrolled 16 participants across 1 site.
Detailed Summary
The primary objective of this study is to compare the efficacy of antecedent intravitreal anti-vascular endothelial growth factor therapy vs. Ozurdex in reducing post-cataract surgery related macular edema in patients with pre-existing diabetic macular edema.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetic Macular Edema, Cataract
CountriesUnited States
CollaboratorsAllergan
Timeline
Phase 4CompletedFinished
20192020202120222023202420252026
Enrollment StartNov 2018
First PostedFeb 2019
Primary CompletionSep 2023
Study CompletionMar 2024
TodayJul 2026
First PostedFeb 6, 2019
Enrollment StartNov 15, 2018
Primary CompletionSep 1, 2023
Study CompletionMar 30, 2024
TodayJul 2, 2026
Enrollment to primary: 4.8 yearsPosted 7.4 years ago
Interventions
Bevacizumabdrug
Bevacizumab
Ranibizumabdrug
Ranibizumab
Afliberceptdrug
Aflibercept
Ozurdexdrug
Ozurdex